Renoprotective effects of dulaglutide in patients with T2DM and CKD

Charlotte M Sorensen; Jens J Holst

doi:10.1038/s41581-018-0055-x

Renoprotective effects of dulaglutide in patients with T2DM and CKD

3 Citations (Scopus)

Abstract

The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.

Original language	English
Journal	Nature Reviews. Nephrology
Volume	14
Issue number	11
Pages (from-to)	659-660
ISSN	1759-5061
DOIs	https://doi.org/10.1038/s41581-018-0055-x
Publication status	Published - 1 Nov 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41581-018-0055-x

https://www.nature.com/articles/s41581-018-0055-x.pdf

Cite this

@article{95994869644143baa2ad734ccb5195dc,

title = "Renoprotective effects of dulaglutide in patients with T2DM and CKD",

abstract = "The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.",

author = "Sorensen, {Charlotte M} and Holst, {Jens J}",

year = "2018",

month = nov,

day = "1",

doi = "10.1038/s41581-018-0055-x",

language = "English",

volume = "14",

pages = "659--660",

journal = "Nature Reviews Nephrology",

issn = "1759-5061",

publisher = "nature publishing group",

number = "11",

}

TY - JOUR

T1 - Renoprotective effects of dulaglutide in patients with T2DM and CKD

AU - Sorensen, Charlotte M

AU - Holst, Jens J

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.

AB - The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.

U2 - 10.1038/s41581-018-0055-x

DO - 10.1038/s41581-018-0055-x

M3 - Comment/debate

C2 - 30171207

SN - 1759-5061

VL - 14

SP - 659

EP - 660

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

IS - 11

ER -

Renoprotective effects of dulaglutide in patients with T2DM and CKD

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this